Intellia Therapeutics Inc (NTLA) concluded trading on Thursday at a closing price of $8.70, with 3.59 million shares of worth about $31.22 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -61.42% during that period and on March 20, 2025 the price saw a loss of about -6.45%. Currently the company’s common shares owned by public are about 102.03M shares, out of which, 97.42M shares are available for trading.
Stock saw a price change of -5.64% in past 5 days and over the past one month there was a price change of -29.15%. Year-to-date (YTD), NTLA shares are showing a performance of -25.39% which decreased to -68.21% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $8.30 but also hit the highest price of $28.54 during that period. The average intraday trading volume for Intellia Therapeutics Inc shares is 3.14 million. The stock is currently trading -12.04% below its 20-day simple moving average (SMA20), while that difference is down -14.70% for SMA50 and it goes to -49.96% lower than SMA200.
Intellia Therapeutics Inc (NASDAQ: NTLA) currently have 102.03M outstanding shares and institutions hold larger chunk of about 90.12% of that.
The stock has a current market capitalization of $900.60M and its 3Y-monthly beta is at 2.13. It has posted earnings per share of -$5.25 in the same period. It has Quick Ratio of 5.77 while making debt-to-equity ratio of 0.24. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for NTLA, volatility over the week remained 7.44% while standing at 8.90% over the month.
Stock’s fiscal year EPS is expected to rise by 11.04% while it is estimated to increase by 5.69% in next year. EPS is likely to grow at an annualized rate of 25.47% for next 5-years, compared to annual growth of -20.04% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on March 05, 2025 offering a Buy rating for the stock and assigned a target price of $30 to it. Coverage by JP Morgan stated Intellia Therapeutics Inc (NTLA) stock as a Neutral in their note to investors on February 28, 2025, suggesting a price target of $13 for the stock. On February 28, 2025, Goldman Downgrade their recommendations, while on January 27, 2025, Morgan Stanley Downgrade their ratings for the stock with a price target of $11. Stock get a Neutral rating from Goldman on February 23, 2024.
